Jaguar Animal Health (NASDAQ:JAGX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Jaguar Animal Health (NASDAQ:JAGX) was downgraded by analysts at
Wall St
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi [Yahoo! Finance]
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication [Yahoo! Finance]
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs [Yahoo! Finance]